Electrical stimulation device for AMD attracts investors

Nova Oculus Partners and StarFish Medical will collaborate to market a pulsed micro-current device for treating both wet and dry AMD.

The non-invasive device uses external battery-operated electrical stimulation to deliver low-intensity electricity that stimulates the production of the active transport enzyme, adenosine trphosphate (ATP). According to recent studies, this treatment improves permeability of the blood vessel membranes and retinal pigment epithelium cells, allows better oxygen and nutrition delivery to the cells, metabolism and removal of by-products from the cells.

StarFish will be responsible for the development and manufacturing of the Nova Oculus headset, an integral component of the electrotherapeutic medical device designed by Nova Oculus. The Canadian-based company expects mass production of the device to begin in early 2017.

Clinical patent trials in Canada are underway. The device is expected to be available for sale in Canada in 2017. While StarFish did not indicate an approval timeline in the United States, it did indicate that the device “meets all the manufacturing protocols required by the U.S. Food and Drug Administration.”